Quantifying anti-inflammatory agents' potency by measurement of response to dinitrochlorobenzene challenge
- PMID: 1390452
- DOI: 10.1016/0923-1811(92)90048-g
Quantifying anti-inflammatory agents' potency by measurement of response to dinitrochlorobenzene challenge
Abstract
Classical assays of topical corticosteroid potency based on the induction of vasoconstriction are unsatisfactory for a number of reasons. These include the doubtful relevance of vasoconstriction to immune inflammation, and more importantly, the inability to compare non-steroidal agents with corticosteroids. Here we describe a simple assay in which the inhibitory effect of agents upon delayed type hypersensitivity response to dinitrochlorobenzene can be quantified by measurements of reaction as skinfold thickness with Harpenden callipers. Using this system we have confirmed the greater potency of clobetasol propionate (Dermovate) compared with betamethasone valerate (Betnovate), but the evidence for an inhibitory effect of topical cyclosporin (10% cream) compared with base on this response is less convincing.
Similar articles
-
The combined effect of topical CX-659S, a novel diaminouracil derivative, with topical corticosteroid on the three types of allergic responses in mice or guinea pigs.J Pharmacol Sci. 2003 Jan;91(1):71-8. doi: 10.1254/jphs.91.71. J Pharmacol Sci. 2003. PMID: 12686733
-
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.Eur J Clin Pharmacol. 1992;42(2):159-61. doi: 10.1007/BF00278477. Eur J Clin Pharmacol. 1992. PMID: 1618247 Clinical Trial.
-
Ranking of the antipsoriatic effect of various topical corticosteroids applied under a hydrocolloid dressing--skin-thickness, blood-flow and colour measurements compared to clinical assessments.Clin Exp Dermatol. 1990 Sep;15(5):343-8. doi: 10.1111/j.1365-2230.1990.tb02109.x. Clin Exp Dermatol. 1990. PMID: 2225536 Clinical Trial.
-
The role of clobetasol propionate emollient 0.05% in the treatment of patients with dry, scaly, corticosteroid-responsive dermatoses.Clin Ther. 1998 Jan-Feb;20(1):26-39. doi: 10.1016/s0149-2918(98)80032-5. Clin Ther. 1998. PMID: 9522102 Review.
-
Side effects of topical glucocorticoids.Curr Probl Dermatol. 1993;21:122-31. doi: 10.1159/000422371. Curr Probl Dermatol. 1993. PMID: 8299365 Review. No abstract available.
Cited by
-
Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone.Br J Clin Pharmacol. 2018 Aug;84(8):1719-1728. doi: 10.1111/bcp.13596. Epub 2018 May 22. Br J Clin Pharmacol. 2018. PMID: 29607554 Free PMC article. Clinical Trial.
-
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.Drugs R D. 2019 Dec;19(4):329-338. doi: 10.1007/s40268-019-00284-1. Drugs R D. 2019. PMID: 31598889 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources